Clinical trials: Endovascular Thrombectomy
Acute Ischemic Stroke
Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)
The main objective of this study is to document that the thrombectomy catheter (Rev-01) is effective and safe when used for revascularization in subjects with acute ischemic stroke within 8 hours of symptom onset who are…
- Trial name
- NCT01895634
- Testing
- Rev-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson K.K. Medical Company
Acute Ischemic Stroke
SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke
SELECT 2 evaluates the efficacy and safety of endovascular thrombectomy compared to medical management alone in acute ischemic stroke patients due to a large vessel occlusion in the distal ICA and MCA M1 who have large core on…
- Trial name
- SELECT2 (NCT03876457)
- Testing
- Endovascular Thrombectomy, Medical Management
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 352 people
- Sponsor
- University Hospitals Cleveland Medical Center
Arterial Ischemic Stroke
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain…
- Trial name
- NCT04962503
- Testing
- Afamelanotide
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Stroke, Acute, Cerebral Infarction
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone…
- Trial name
- DEFUSE 3 (NCT02586415)
- Testing
- Endovascular Thrombectomy, Trevo Retriever, Solitaire™ FR Revascularization Device
- Where
- 40 sites in United States
- Volunteers
- 182 people
- Sponsor
- Gregory W Albers
Stroke, Ischemic
Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular revascularization.
- Trial name
- RESCUE (NCT04693715)
- Testing
- RNS60
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- Revalesio Corporation
Acute Stroke, Endovascular Thrombectomy
Blood Pressure After Endovascular Stroke Therapy-II
The purpose of this study is to assess the safety of lowering blood pressure in acute stroke patients that are successfully treated with a mechanical thrombectomy procedure.
- Trial name
- BEST-II (NCT04116112)
- Testing
- Nicardipine, Labetalol, Hydralazine
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Cincinnati
Acute Ischemic Stroke
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset…
- Trial name
- SWIFT PRIME (NCT01657461)
- Testing
- Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Stroke, Acute
Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct…
- Trial name
- ESCAPE-NA1 (NCT02930018)
- Testing
- Nerinetide (NA-1), 2.6 mg/kg
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 1,105 people
- Sponsor
- NoNO Inc.
Stroke
Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure
The purpose of this First-in-Human study is to evaluate the safety of using the Clotild® system to guide the endovascular thrombectomy (EVT) device to the clot location during EVT for the treatment of an acute ischemic stroke…
- Trial name
- CLOTOUT (NCT04993079)
- Testing
- Clotild® Smart Guidewire System (CSGS)
- Where
- 3 sites in Australia, France
- Volunteers
- 45 people
- Sponsor
- Sensome
Ischemic Stroke
Treatment With Intent to Generate Endovascular Reperfusion
Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset.
- Trial name
- TIGER (NCT03474549)
- Testing
- Tigertriever revascularization device
- Where
- 17 sites in United States, Israel
- Volunteers
- 160 people
- Sponsor
- Rapid Medical
Stroke, Acute
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen…
- Trial name
- ESCAPE-NEXT (NCT04462536)
- Testing
- Nerinetide
- Where
- 81 sites in United States, Australia and 7 more
- Volunteers
- 850 people
- Sponsor
- NoNO Inc.